Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.

Abstract

One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases. Herein, we report a case of a 74-year-old male CML patient with intracranial stenosis of the internal carotid artery developed during treatment with nilotinib successfully cured by the intracranial stent, Wingspan.

• Authors: Tomohiko Ozaki, Hajime Nakamura, Nobuyuki Izutsu, Hiroaki Masaie, Jun Ishikawa, Manabu Kinoshita
• Journal: Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences (Interv Neuroradiol) Vol. 23 Issue 5 Pg. 527-530 (Oct 2017) ISSN: 2385-2011 [Electronic] United States
• PMID: 28583043 (Publication Type: Case Reports, Journal Article)

Chemical References

• Pyrimidines
• Protein-Tyrosine Kinases
• nilotinib

Topics

• Aged
• Carotid Artery, Internal
• Carotid Stenosis (chemically induced, therapy)
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (complications)
• Male
• Protein-Tyrosine Kinases (adverse effects)
• Pyrimidines (adverse effects)
• Stents